Hrain Biotechnology is adhering to the concept of treating diseases and saving people.
Hrain Biotechnology is a tumor immunotherapy technology developer, using the tumor immunotherapy technology CAR-T to provide cancer patients with precise treatment based on biological and cellular technology, and built centers in Beijing, Jiangsu, Chongqing, Henan and other places. Clinical trial platform.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 30, 2019 | Series B | ¥200M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ChiNext Qianhai Capital | — | Series B |
Junchenda Capital | — | Series B |